GlassScriptPhysician profile
Danielle Avila
NPI 1568295582
$2,138.90
in general payments reported to CMS, 2019-2025
11 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $265 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,377 · Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,377.16 |
| Food and Beverage | $761.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,595.49 | 2025 | Minimed 780g |
| Abbvie INC. | $123.35 | 2025 | |
| Dexcom, INC. | $116.13 | 2024 | Dexcom G7 Gss (161) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.45 | 2024 | Xifaxan |
| Lilly USA, LLC | $50.56 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Jazz Pharmaceuticals INC. | $35.93 | 2025 | |
| Novo Nordisk INC | $34.52 | 2025 | Wegovy, Saxenda, Ozempic |
| Astrazeneca Pharmaceuticals LP | $20.97 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $16.40 | 2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $15.90 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $14.20 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.